Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nabilone for Non-motor Symptoms in PD (NMS-Nab2)
NCT03773796Phase 3Completed
- Sponsor
- Medical University of Innsbruck
- Start
- Aug 2018
- Primary completion
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of nabilone in Parkinson's disease (PD), sponsored by Medical University of Innsbruck. Primary endpoints: Adverse Events in PD Patients Taking Nabilone at 6 months, Number of Subjects Who Discontinue the Study Due to an AE at 6 months and 7 more. Started Aug 2018; status: completed.
02
Drugs
nabilone
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT03773796.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03773796.